Retatrutide Showcases Historic Weight-Lowering, Glycemic Con

Data from a pair of phase 2 trials in patients with overweight/obesity and type 2 diabetes presented at ADA 2023 suggest the GIP/GLP-1/Glucagon agonist retatrutide could provide significant weight loss and glycemic control benefits.

Related Keywords

United States , American , Ania Jastreboff , Dan Skovronsky , Eli Lilly , Triumph , Scientific Sessions Of The American Diabetes Association , Yale Obesity Research Center , Yale School Of Medicine Ania Jastreboff , Yale Center , Lilly Research Laboratories , Yale School Of Medicine , Yale School , Scientific Sessions , American Diabetes Association , New England Journal , Associate Professor , Lilly Research , Hormone Receptor Agonist Retatrutide , Medicine Show , Investigational Molecule ,